Please wait...


Generic Name: rucaparib (roo KAP a rib)
Brand Names: Rubraca
Rubraca (rucaparib) is used to treat advanced BRCA ovarian cancer. Includes Rubraca side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Rubraca

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Rubraca (rucaparib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Rubraca is used to treat advanced ovarian cancer. Rubraca is used only if your tumor has a specific genetic marker, for which your doctor will test. Rubraca is usually given after at least 2 other cancer medicines have been tried without success. Rubraca can cause leukemia or serious bone marrow problems. You may get an infection or bleed more easily. Call your doctor if you have unusual bruising or bleeding, blood in your urine or stools, shortness of breath, or signs of infection (fever, feeling weak or tired, weight loss). Learn more

Rubraca Side Effects

Rubraca Side Effects

Note: This document contains side effect information about rucaparib. Some of the dosage forms listed on this page may not apply to the brand name Rubraca.

For the Consumer

Applies to rucaparib: oral tablet

Along with its needed effects, rucaparib (the active ingredient contained in Rubraca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking rucaparib:

More common

  • Black, tarry stools
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blood in the urine
  • body aches or pain
  • chills
  • cough
  • difficulty in breathing
  • ear congestion
  • fever
  • headache
  • loss of voice
  • lower back or side pain
  • muscle aches
  • nasal congestion
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • rapid weight gain
  • sneezing
  • sore throat
  • stuffy or runny nose
  • tingling of the hands or feet
  • trouble breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss

Less common

  • Redness, swelling, or pain of the skin
  • scaling of the skin on the hands and feet
  • tenderness of the palms and soles
  • tingling of the hands and feet
  • ulceration of the skin

Some side effects of rucaparib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Belching
  • change in taste
  • constipation
  • decreased appetite
  • diarrhea
  • discouragement
  • dizziness
  • feeling sad or empty
  • heartburn
  • increased sensitivity of the skin to sunlight
  • indigestion
  • irritability
  • itching, skin rash
  • lack of appetite
  • lack or loss of strength
  • loss of interest or pleasure
  • loss of taste
  • nausea
  • redness or other discoloration of the skin
  • severe sunburn
  • stomach discomfort, upset, or pain
  • stomach distention
  • swelling or inflammation of the mouth
  • trouble concentrating
  • trouble sleeping
  • vomiting

For Healthcare Professionals

Applies to rucaparib: oral tablet


-The most common adverse reactions reported in at least 20% of patients were nausea, asthenia/fatigue, vomiting, anemia, constipation, dysgeusia, decreased appetite, diarrhea, abdominal pain, dyspnea, and thrombocytopenia.

-The most common laboratory abnormalities reported in at least 35% of patients were increased creatinine, increased ALT, increased AST, decreased hemoglobin, decreased lymphocytes, increased cholesterol, decreased platelets, and decreased absolute neutrophil count.

-Adverse reactions led to dose reduction or interruption in 62% of patients (most frequently from anemia [27%] and asthenia/fatigue [22%]), and to dose discontinuation in 10% of patients (most frequently from asthenia/fatigue [2%]).


Very common (10% or more): Increased creatinine (92%)


Very common (10% or more): Nausea (77%), vomiting (46%), constipation (40%), diarrhea (34%), abdominal pain (32%)


Very common (10% or more): Asthenia/fatigue (77%), pyrexia (11%)


Very common (10% or more): Increased ALT (74%), increased AST (73%)


Very common (10% or more): Decreased hemoglobin (67%), decreased lymphocytes (45%), anemia (44%), decreased platelets (39%), decreased absolute neutrophil count (35%), thrombocytopenia (21%), neutropenia (15%)

Common (1% to 10%): Febrile neutropenia


Very common (10% or more): Decreased appetite (39%), increased cholesterol (40%)

Nervous system

Very common (10% or more): Dysgeusia (39%), dizziness (17%)


Very common (10% or more): Dyspnea (21%)


Very common (10% or more): Dermatitis/Rash (13%), photosensitivity reaction (10%)

Common (1% to 10%): Pruritus, palmar-plantar erythrodysesthesia syndrome


Uncommon (0.1% to 1%): Myelodysplastic syndrome, acute myeloid leukemia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Rubraca